Ewgenij Proschak

This paper introduces a miniaturized PROTAC synthesis workflow that bypasses compound purification, enabling rapid screening and degradation assessment of multiple targets.

The paper identifies the transaminase-omega-amidase pathway as a redox-sensitive metabolic switch in endothelial glutamine metabolism, showing that NIT2 oxidation inhibits its activity and affects angiogenesis.

This paper designs and tests sEH-PROTACs to degrade soluble epoxide hydrolase, identifying PROTAC 23 as effective in degrading sEH in human macrophages.

This paper develops a miniaturized Direct-to-Biology platform for rapid PROTAC degrader synthesis and screening, identifying potent sEH degraders with subnanomolar activity.

The paper evaluates the druggability of LC3/GABARAP for autophagy modulators and identifies ligands that bind to the HP2 pocket of the LIR docking site.

The paper introduces an ultrahigh-throughput strategy to discover modified aptamers as specific and potent enzyme inhibitors, demonstrating its effectiveness with an inhibitor of SPM-1.

The paper identifies epoxykynin as a potent sEH inhibitor that modulates the kynurenine pathway, offering new opportunities to address cancer-induced immune tolerance.

This study identifies compound 6 as a potent Slack potassium channel activator effective in treating histamine-independent and chronic itch without motor side effects.